{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'efficacy at final ORR analysis', 'was modified.', 'Section 11 References', 'GSK2857916 IB version updated from', 'Updated to include most recent', '03 to 05', 'version of IB', 'Section 12.5', 'New template language added to', 'Clarifies notification needed \"for', 'Contraception Guidance', 'elective termination description', 'medical reasons\"', 'Section 12.7 Liver', 'Removed non-applicable PK sample', 'Comparator language removed', 'Chemistry Stopping', 'statements in footnote 6', 'since monotherapy study', 'Criteria', 'Clarification', 'PK collection interval updated to 5 half-', 'Updated timeframe during', 'lives', 'which drug concentrations', 'should be measured', '12.9 Corneal Event', 'Added clarification that Grading is a', 'To align with Section 9.2', 'Severity Grading and', 'GSK Scale', 'Adverse Events and to indicate', 'Mitigation Strategy', 'the GSK Scale for corneal', 'Footnotes updates', 'Table 22', 'events is not a CTCAE scale', '12.10 Modified Diet in', 'MDRD formula for calculating the', 'Provides instruction for', 'Renal Disease (MDRD)', 'estimated glomerular filtration rate was', 'calculation of eGFR', 'Formula', 'clarified to show superscript values', 'The numbers in the Table 24 in', '12.12 Appendix 12', 'Table 24 clear version inserted', 'previous version were not', 'Modified description of simulation', 'legible.', 'studies for evaluating operating', 'characteristics', 'To clarify the objectives and', 'conduct of simulation studies', 'Throughout', 'Minor editorial and document', 'Minor, therefore have not been', 'formatting revisions', 'summarized', 'Amendment 1: 02 April 2018', 'Overall Rationale for the Amendment:', 'The protocol has been amended to address regulatory agency advice. The original single-', 'arm design with 1 dose level (3.4 mg/kg GSK2857916 Q3W) was amended to an', 'open-label, randomized, 2-arm study with 2 dose levels by including the 2.5 mg/kg Q3W', 'dose. In addition, a new exploratory cohort of 25 participants, who will receive a', 'lyophilized configuration of GSK2857916, has been added to gain clinical experience', '143']['2017N330177_0', 'CONFIDENTIAL', '205678', 'with the lyophilized configuration. To accommodate these main changes, the overall', 'sample size and related analytical methods have been changed.', 'DOCUMENT HISTORY', 'Document', 'Date of Issue', 'Amendment 3', '17-Dec-2018', 'Amendment 2 (Republishing)', '04-Sep-2018', 'Amendment 2', '30-Aug-2018', 'Amendment 1', '02-Apr-2018', 'Original Protocol', '18-Jan-2018', '144']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Cover Page', 'Study title updated', 'Title updated to reflect the design', 'A Phase II, Open Label,', 'change (see below)', 'Randomized, Two-Arm Study to', 'Investigate the Efficacy and Safety of', 'Two Doses of the Antibody Drug', 'Conjugate GSK2857916 in', 'Participants with Multiple Myeloma', 'Who Had 3 or More Prior Lines of', 'Treatment, Are Refractory to a', 'Proteasome Inhibitor and an', 'Immunomodulatory Agent and Have', 'Failed an Anti-CD38 Antibody', '(DREAMM 2).', 'Synopsis', 'Changed text of Synopsis to reflect', 'See below for all significant', 'changes to the text of the protocol', 'changes', 'All sections', 'Replaced the word \"patient\\' with', '\"participant\\' and \\'subset\\' replaced', 'with \"sub-study\\'.', 'New references added', 'Section 2 Schedule of', 'Separate schedule tables for', 'The tables have been separated', 'Activities', 'Screening assessments, on study', 'to clarify activities.', \"assessment, 'end of treatment\", 'assessment and follow-up', 'assessment have been included.', 'Deletion of coagulation criteria (INR)', 'Current liver event management', 'for determining adequate organ', 'guidelines do not require INR.', 'system function', 'Flow cytometry is not used in', 'Removal of aspirate for flow', 'IMWG Kumar, 2016.', 'cytometry', 'Based on Kumar, 2016.', 'Added PET/CT to confirm CR, sCR', 'Germany: approval by the', 'German Federal Office for', 'Radiation Protection is required', 'German exceptions to PET/CT', 'prior to PET/CT or other x-rays', 'can be performed.', '145']\n\n###\n\n", "completion": "END"}